Genetic components such as the APOE ε4 allele, which is responsible for Alzheimer’s disease, and mutations in LRRK2, which are responsible for Parkinson’s disease, are now facilitating the development of individualized approaches for neurosurgical or pharmacological treatments [13]. This evidence concerns the gene LRRK2 and Parkinson disease.